Argenx

News

Argenx dealt another blow as Vyvgart Hytrulo fails again

Shares in Argenx have been taking a bashing this morning after the company announced its new subcutaneous formulation of Vyvgart had missed the mark in another phase 3 tri

News

Shine rubs off Argenx after Vyvgart Hytrulo fails trial

Argenx has been riding high of late thanks to buoyant sales growth for its Vyvgart therapy for muscle-wasting disease generalised myasthenia gravis (gMG), but a failed pha

News

UCB stakes claim to gMG market as FDA clears Rystiggo

The FDA has become the first global regulator to approve UCB’s Rystiggo, a treatment for generalised myasthenia gravis that the company says is the only drug that can be u

News

Argenx gets FDA nod for first subcutaneous gMG therapy

The market for drugs to treat the muscle-wasting disease generalised myasthenia gravis (gMG) is getting more crowded, and Argenx has just claimed an FDA approval that coul

News

ASH: Argenx cues up a second use for efgartigimod

Dutch biotech Argenx is on course to add another rare disease indication to the label of its FcRn blocker Vyvgart – for primary immune thrombocytopenia (ITP) – thanks to new data reported a

News

UK grants early access to Argenx' efgartigimod for myastheni...

The UK regulatory authority has cleared the path for some patients with generalised myasthenia gravis (gMG) to get early access to Argenx' efgartigimod while it reviews the marketing applic

Argenx dealt another blow as Vyvgart Hytrulo fails again

Shine rubs off Argenx after Vyvgart Hytrulo fails trial

UCB stakes claim to gMG market as FDA clears Rystiggo

Argenx gets FDA nod for first subcutaneous gMG therapy

ASH: Argenx cues up a second use for efgartigimod

UK grants early access to Argenx' efgartigimod for myastheni...

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Argenx

Editor's Picks